BridgeMD
Optimizing Aspirin Use for Preeclampsia Prevention
EU CTIS ID: 2025-524646-94-00
What this study is testing
To evaluate whether stopping ASA between weeks 24 and 26 is non-inferior in preventing preterm preeclampsia compared to the control group, which will continue ASA until week 36
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients older than 18 years
- Ability to read and understand the informed consent
- Singleton pregnancy
- Having undergone first-trimester preeclampsia screening (11+0 to 13+6 weeks) using a multiparametric algorithm and being classified as high risk.
- Voluntary informed consent signature and willing to comply with study protocol (including acceptance of aspirin [ASA] treatment, additional blood tests and ultrasounds, and the assigned treatment duration at randomization).
You likely can't join if
- Early pregnancy loss, stillbirth or fetus with major malformations
- Fetus affected by a known genetic or chromosomal disease
- Contraindication, allergy, or intolerance to aspirin (AAS)
- Inability to discontinue aspirin (e.g., antiphospholipid syndrome, etc.)
The study team makes the final eligibility decision.
Where it's taking place
- United Kingdom
- Senegal
- Ghana
- Gambia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United Kingdom; Senegal; Ghana; Gambia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.